Figure A2.

Patient flow diagram for patients initiating lapatinib following 1L trastuzumab. * Date on or prior to 31 December 2019 that treatment with lapatinib was initiated. ^† Death prior to the mBC diagnosis date. ^‡ Date T-DM1 was approved by the US Food and Drug Administration. 1L = first line; 2L = second line; eBC = early breast cancer; mBC = metastatic breast cancer; pts = patients.